IL241325A0 - Salt-induced macrocyclic kinase inhibitors - Google Patents
Salt-induced macrocyclic kinase inhibitorsInfo
- Publication number
- IL241325A0 IL241325A0 IL241325A IL24132515A IL241325A0 IL 241325 A0 IL241325 A0 IL 241325A0 IL 241325 A IL241325 A IL 241325A IL 24132515 A IL24132515 A IL 24132515A IL 241325 A0 IL241325 A0 IL 241325A0
- Authority
- IL
- Israel
- Prior art keywords
- macrocyclic
- salt
- kinase inhibitors
- inducible kinase
- inducible
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2013055389 | 2013-03-15 | ||
| PCT/EP2014/055168 WO2014140313A1 (en) | 2013-03-15 | 2014-03-14 | Macrocyclic salt-inducible kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL241325A0 true IL241325A0 (en) | 2015-11-30 |
Family
ID=50588637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL241325A IL241325A0 (en) | 2013-03-15 | 2015-09-08 | Salt-induced macrocyclic kinase inhibitors |
Country Status (13)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1218263A1 (zh) * | 2013-03-15 | 2017-02-10 | 昂科迪塞恩股份有限公司 | 大环rip2激酶抑制剂 |
| CA2954186A1 (en) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| WO2018009544A1 (en) | 2016-07-05 | 2018-01-11 | The Broad Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| US11241435B2 (en) | 2016-09-16 | 2022-02-08 | The General Hospital Corporation | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis |
| EP3589284A4 (en) | 2017-02-28 | 2020-12-16 | The General Hospital Corporation | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS |
| DK3391907T3 (da) | 2017-04-20 | 2020-03-09 | Iomx Therapeutics Ag | Intracellulær kinase sik3, der er associeret med resistens over for antitumorimmunresponser, og anvendelser deraf |
| CN109956957B (zh) * | 2017-12-22 | 2021-11-09 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
| WO2020027200A1 (ja) | 2018-08-01 | 2020-02-06 | 小野薬品工業株式会社 | 軟骨関連疾患治療剤 |
| US11690897B2 (en) | 2019-02-04 | 2023-07-04 | The Board Of Trustees Of The University Of Illinois | Salt inducible kinase inhibitors for enhancing fertility |
| CN115698020B (zh) * | 2020-01-31 | 2025-02-25 | 昂科迪塞恩精密医药公司(Opm) | 大环rip2-激酶抑制剂 |
| AU2023339247A1 (en) * | 2022-09-07 | 2025-03-27 | Suzhou Langrui Biopharmaceutical Co., Ltd. | Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| CZ289214B6 (cs) | 1993-10-01 | 2001-12-12 | Astra Aktiebolag | Způsob zpracování jemně děleného práąkového léčiva, zařízení k provádění tohoto způsobu a aglomeráty vyrobené tímto způsobem |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US7517882B2 (en) * | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| MX2009004700A (es) * | 2006-11-06 | 2009-05-15 | Supergen Inc | Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa. |
| WO2008060248A1 (en) * | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| ES2548135T3 (es) * | 2008-05-13 | 2015-10-14 | Novartis Ag | Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa |
| AU2012314035B2 (en) * | 2011-09-30 | 2016-12-15 | Oncodesign S.A. | Macrocyclic LRRK2 kinase inhibitors |
| US9090630B2 (en) * | 2011-09-30 | 2015-07-28 | Oncodesign S.A. | Macrocyclic FLT3 kinase inhibitors |
-
2014
- 2014-03-14 AU AU2014230125A patent/AU2014230125A1/en not_active Abandoned
- 2014-03-14 CN CN201480023832.3A patent/CN105209040A/zh active Pending
- 2014-03-14 BR BR112015022650A patent/BR112015022650A8/pt not_active IP Right Cessation
- 2014-03-14 US US14/776,798 patent/US9586975B2/en not_active Expired - Fee Related
- 2014-03-14 KR KR1020157029486A patent/KR20150133767A/ko not_active Withdrawn
- 2014-03-14 EA EA201591794A patent/EA201591794A1/ru unknown
- 2014-03-14 WO PCT/EP2014/055168 patent/WO2014140313A1/en not_active Ceased
- 2014-03-14 CA CA2906262A patent/CA2906262A1/en not_active Abandoned
- 2014-03-14 HK HK16107168.3A patent/HK1219057A1/zh unknown
- 2014-03-14 MX MX2015012528A patent/MX2015012528A/es unknown
- 2014-03-14 SG SG11201507493SA patent/SG11201507493SA/en unknown
- 2014-03-14 JP JP2015562215A patent/JP2016510797A/ja not_active Ceased
-
2015
- 2015-09-08 IL IL241325A patent/IL241325A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014140313A1 (en) | 2014-09-18 |
| HK1219057A1 (zh) | 2017-03-24 |
| MX2015012528A (es) | 2016-04-15 |
| EA201591794A1 (ru) | 2015-12-30 |
| BR112015022650A2 (pt) | 2017-07-18 |
| US20160024113A1 (en) | 2016-01-28 |
| CN105209040A (zh) | 2015-12-30 |
| AU2014230125A1 (en) | 2015-10-29 |
| BR112015022650A8 (pt) | 2018-01-23 |
| US9586975B2 (en) | 2017-03-07 |
| KR20150133767A (ko) | 2015-11-30 |
| SG11201507493SA (en) | 2015-10-29 |
| CA2906262A1 (en) | 2014-09-18 |
| JP2016510797A (ja) | 2016-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201508125XA (en) | Protein kinase inhibitors | |
| IL245672A0 (en) | Pyrimidopyrimidinones used as wee-1 kinase inhibitors | |
| IL245807A0 (en) | Apoptosis signal-modulating kinase inhibitors | |
| IL241325A0 (en) | Salt-induced macrocyclic kinase inhibitors | |
| IL239827A0 (en) | Deoxyuridine triphosphatase inhibitors | |
| EP2986611A4 (en) | CERTAIN PROTEIN KINASE INHIBITORS | |
| PL2634185T3 (pl) | Inhibitory kinazy TYK2 | |
| ZA201506327B (en) | Macrocyclic lrrk2 kinase inhibitors | |
| PT2952510T (pt) | Inibidor de proteína-cinase de 2-aminopiridina substituída | |
| ZA201603833B (en) | Tropomyosin-related kinase (trk) inhibitors | |
| GB201314578D0 (en) | Bicyclic inhibitors | |
| ZA201604461B (en) | Serine/threonine kinase inhibitors | |
| EP2870158A4 (en) | PROTEIN KINASE INHIBITORS | |
| IL241250A0 (en) | Macrocyclic inhibitors of rip2 kinase | |
| EP2855484A4 (en) | PROTEIN KINASE INHIBITORS | |
| IL244029A0 (en) | Deoxycytodine kinase inhibitors | |
| EP2900243A4 (en) | BICYCLIC OXA LACTAM KINASE HEMMER | |
| GB201304714D0 (en) | Macrocyclic RIP2 Kinase inhibitors | |
| GB201307155D0 (en) | Kinase inhibitors | |
| GB201323021D0 (en) | Use of kinase inhibitors | |
| GB201321227D0 (en) | Use of kinase inhibitors | |
| GB201309603D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201305741D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201404570D0 (en) | Macrocyclic kinase inhibitors | |
| GB201404555D0 (en) | Macrocyclic kinase inhibitors |